Matteo Ruggeri

Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

Paolo Caraceni, Oliviero Riggio, Paolo Angeli et al. · The Lancet · 2018 · 499 citations · Full text

Hepatology, Decompensated Cirrhosis, Liver Physiology +6

Costs of Bloodstream Infections Caused by <i>Escherichia coli</i> and Influence of Extended-Spectrum-β-Lactamase Production and Inadequate Initial Antibiotic Therapy

Mario Tumbarello, Teresa Spanu, Rossella Di Bidino et al. · Antimicrobial Agents and Chemotherapy · 2010 · 199 citations · Full text

Escherichia Coli, Antibiotic Resistance, Bacterial Pathogens +19

Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study

Luisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci et al. · Journal of Crohn s and Colitis · 2018 · 75 citations

Telemedicine as technoinnovation to tackle COVID-19: A bibliometric analysis

Carlo Drago, Andrea Gatto, Matteo Ruggeri · Technovation · 2021 · 73 citations · Full text

Wireless Telemedicine, Telemedicine, Global Health +8

Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C

Calogero Cammà, Salvatore Petta, Giuseppe Cabibbo et al. · Journal of Hepatology · 2013 · 57 citations

Vaccination, Hepatology, Hepatitis C +9